Advancements in proteomics and multi-omic technologies empower the identification of protein biomarkers from serum and plasma in a scalable manner. Herein, 416 plasma samples derived from donors undiagnosed or with Stage I or IV prostate, lung, or colorectal cancer were profiled using high throughput Thermo Orbitrap Astral mass spectrometry (MS) and Olink® Explore HT.
